Ignite Creation Date:
2025-12-24 @ 9:49 PM
Ignite Modification Date:
2026-01-02 @ 1:47 PM
Study NCT ID:
NCT05507632
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-08-19
First Post:
2022-08-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
Sponsor:
Nanfang Hospital, Southern Medical University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
NFEC-2022-256
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None